Register
Login:
Share:
Email Facebook Twitter

James Bevan on cybersecurity, banks and the housing market Watch here

James Bevan on cybersecurity, banks and the housing market


Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 54.50Bid: 54.00Ask: 54.50Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 0.50Spread as %: 0.93%Open: 55.25High: 56.00Low: 54.50Yesterday’s Close: 54.50

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
54.50

Share Price SpacerBid
54.00

Share Price SpacerAsk
54.50

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
220,147

Share Price SpacerOpen
55.25

Share Price SpacerHigh
56.00

Share Price SpacerLow
54.50

Share Price SpacerClose
54.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 132.52m £72.23m 5,000

52 Week High 69.00 52 Week High Date 17-FEB-2017
52 Week Low 28.00 52 Week Low Date 25-MAY-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
30 160,523 59,624 -12.386 -4.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

19-May-17
16:13:10
55.00
90,943
Buy* 
54.00
54.50
50.02k
Trade Type:
Ordinary

22-May-17
16:47:34
56.00
500
Buy* 
54.00
54.50
280.00
Trade Type:
Ordinary
Bargain conditions apply

22-May-17
16:35:22
54.50
24,478
Buy* 
54.00
54.50
13.34k
UT 
Trade Type:
Uncrossing Trade




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Mon 19:55LostinfranceRE: Announcement54.50No Opinion
So why the delay dibs? The last 5 years the results were either april or early may, no reason for the delay this year,
And still no news on the early pipeline even though the last money raised was to push this forward,

No one kniws and all guesswork, we must wait and see,
Mon 19:26Dibs61RE: Announcement54.50No Opinion
I beg to differ. If you had a deal you wouldnt want to release it with the results, why?? For what purpose? You'd simply issue a stand alone RNS particularly for such an important issue. For a development company like this the financial results are purely academic - no revenue.
Mon 18:50LostinfranceRE: Announcement54.50No Opinion
In my view there must be a reason for the results to be delayed by a month, if they had nothing else to add they would have released them now,
Last weeks rns was solely for the lupuzor trial,

We know they wanted to progress the early stage portfolios, also the cancer ph 11 trial, so any of this could be announced,
We also know they were talking to interested parties, any discussions would not be disclosed to private investors untill a deal is signed, for all we know everything is in place… Read More
Mon 11:35JdubyaRE: Announcement55.00Strong Buy
Many thanks leas and Jdoe. I'm not expecting any deal as such. More likely confirmation that they are still talking to interested parties. At this stage, I am now more interested with other advancements. Lupuzor updates would seem to be updated every few months and as we have just had one, I doubt there would be anything new. Today's rns still remains odd though if they have never done this but it could just be because they are late. All the best
Mon 10:53Dibs61Results55.00Buy
We are setting ourselves up for disappointment to imagine there is going to be a 'deal' included in the announcement. I suggest it will be just the results which is fine. Maybe an update on progress elsewhere of course which will be good.

What will move the SP is when the market starts to believe the unfolding story and we all know how fickle the market can be. I can wait.
Mon 10:15leasRE: Announcement55.00No Opinion
No previous RNS, just the finals. I can only guess that they have issued a RNS because the are now overdue. We know P140 is on track with no reported safety issues so don't know what has delayed them. If a deal is being worked on then a NDC would be in play so everything would be pure speculation.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.